Confident Investing Starts Here:
- Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter
An announcement from Ocugen ( (OCGN) ) is now available.
On June 22, 2025, Ocugen, Inc. and its subsidiary OrthoCellix, Inc. entered into a merger agreement with Carisma Therapeutics Inc. and its subsidiary, Azalea Merger Sub, Inc. This merger will result in OrthoCellix becoming a wholly-owned subsidiary of Carisma, with the combined company focusing on OrthoCellix’s NeoCart® technology for knee cartilage repair. The merger, expected to close in the second half of 2025, will see Ocugen and investors owning approximately 90% of the combined company, with Carisma stockholders holding the remaining 10%. The transaction aims to create a Nasdaq-listed company dedicated to regenerative cell therapies for orthopedic diseases, with plans to initiate a Phase 3 clinical trial for NeoCart® by the end of 2025.
The most recent analyst rating on (OCGN) stock is a Buy with a $8.00 price target. To see the full list of analyst forecasts on Ocugen stock, see the OCGN Stock Forecast page.
Spark’s Take on OCGN Stock
According to Spark, TipRanks’ AI Analyst, OCGN is a Neutral.
Ocugen’s stock score is driven by significant financial challenges, despite promising technical indicators and strategic advancements. The company’s ongoing losses and reliance on financing are major concerns, but progress in gene therapy and strategic partnerships offer some optimism.
To see Spark’s full report on OCGN stock, click here.
More about Ocugen
Ocugen, Inc. is a clinical-stage company focused on developing regenerative cell therapies for orthopedic diseases. Its wholly-owned subsidiary, OrthoCellix, Inc., is dedicated to creating a first-in-class technology platform targeting cartilage defects and other orthopedic conditions. The lead program within OrthoCellix is NeoCart®, a revolutionary 3D cell therapy technology designed to repair and restore articular cartilage defects in the knee.
Average Trading Volume: 4,620,417
Technical Sentiment Signal: Hold
Current Market Cap: $309.6M
See more insights into OCGN stock on TipRanks’ Stock Analysis page.